Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05525026 · ClinicalTrials.gov registry record · NA

Evaluation of Safety and Efficacy of the BTL-785F Device for Non-invasive Facial Remodeling

A NA study, sponsored by BTL Industries.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT05525026: Completed NA study, sponsored by BTL Industries.

NCT05525026 is a NA study that has completed, run by BTL Industries. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05525026, a NA study, has completed, sponsored by BTL Industries.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive facial remodeling.

Primary Outcome

Evaluation of facial skin appearance based on photographs before and after the study procedure according to the Global Aesthetic Improvement Scale.The GAIS is a clinically validated assessment tool used to assess overall aesthetic improvement such as facelift on a scale from -1 through 3, where the higher score is considered better.

Interventions

  • DEVICE BTL-785-7

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2021-12-08
Est. Completion 2023-02-15
Phase NA
BTL Industries

40 total trials

What the finished NCT05525026 record still lists

NCT05525026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which BTL-785-7 is the first listed.

NCT05525026 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05525026 about?

NCT05525026 is a clinical study titled "Evaluation of Safety and Efficacy of the BTL-785F Device for Non-invasive Facial Remodeling". This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive facial remodeling.

What is the current status of trial NCT05525026?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2021-12-08. Estimated completion is 2023-02-15.

What interventions are being tested in trial NCT05525026?

The interventions under investigation include: BTL-785-7 (DEVICE).

Who is sponsoring clinical trial NCT05525026?

This trial is sponsored by BTL Industries, which has 40 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05525026's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05525026, the US trial registry maintained by the National Library of Medicine. NCT05525026 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.